The abstract is read at the publisher; the summary is JClub's.
MIMAC microfluidics restructures preformed mRNA lipid nanoparticles to create a peripheral-to-core RNA layout, boosting ATP up to 4.2-fold and enhancing subsequent therapeutic translation.
- Why it matters: mRNA lipid nanoparticle therapies still face bottlenecks in limited cellular expression and in encapsulation and release kinetics that are hard to control.
- What they did: The method uses rapid shear to insert a metabolic enhancing RNA into an internal peripheral compartment while moving the therapeutic RNA toward the core, enabling sequential cytosolic availability.
- The result: In mice, the structured nanoparticles improve a human papillomavirus cancer vaccine with 89.2% tumour growth suppression and higher survival, and for SARS-CoV-2 they raise antibody titres 62.3- to 174.8-fold at one-tenth dose.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.